Top Page
ATAI Life Sciences
(NASDAQ:ATAI)
ATAI Life Sciences (ATAI) vs. SPDR S&P 500 ETF (SPY)
ATAI Life Sciences Business Overview & Revenue Model
ATAI Life Sciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.31M | 308.00K | 314.00K | 233.00K | 20.38M | 0.00 |
| Gross Profit | 2.31M | 308.00K | 314.00K | 65.00K | 20.33M | -24.00K |
| EBITDA | -115.81M | -145.33M | -36.31M | -135.01M | -120.28M | -92.12M |
| Net Income | -119.40M | -149.27M | -40.22M | -141.41M | -132.61M | -102.12M |
Balance Sheet | ||||||
| Total Assets | 189.20M | 159.39M | 293.48M | 305.44M | 414.17M | 111.55M |
| Cash, Cash Equivalents and Short-Term Investments | 95.94M | 62.33M | 179.26M | 273.11M | 362.27M | 97.25M |
| Total Debt | 9.22M | 24.71M | 19.14M | 15.12M | 743.00K | 2.18M |
| Total Liabilities | 45.28M | 42.83M | 49.16M | 300.42M | 28.21M | 16.18M |
| Stockholders Equity | 143.74M | 116.30M | 242.96M | 260.74M | 376.91M | 90.82M |
Cash Flow | ||||||
| Free Cash Flow | -80.79M | -82.53M | -84.71M | -105.49M | -64.37M | -20.82M |
| Operating Cash Flow | -75.57M | -82.44M | -84.12M | -104.47M | -63.25M | -20.77M |
| Investing Cash Flow | 30.17M | 59.17M | -53.30M | -86.85M | -81.28M | -28.27M |
| Financing Cash Flow | 72.41M | 5.37M | -8.36M | 20.79M | 409.86M | 113.05M |
ATAI Life Sciences Technical Analysis
ATAI Life Sciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.19B | 5.78 | ― | ― | 799.36% | ― | |
58 Neutral | $4.31B | -13.04 | -75.20% | ― | 364.98% | -25.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.03B | ― | -180.24% | ― | -32.79% | 36.87% | |
49 Neutral | $1.25B | ― | -171.41% | ― | -14.98% | -51.76% | |
43 Neutral | $1.22B | ― | -43.82% | ― | ― | -7.33% | |
41 Neutral | $1.13B | ― | ― | ― | ― | ― |
ATAI Life Sciences Corporate Events
On November 5, 2025, Atai Beckley N.V. filed a prospectus supplement with the SEC related to the resale of 5,316,238 common shares. This action is part of fulfilling registration rights granted during the acquisition of Beckley Psytech Limited, impacting the company’s share distribution and potentially its market standing.
The most recent analyst rating on (ATAI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
On November 5, 2025, Atai Beckley N.V. completed its acquisition of Beckley Psytech Limited, resulting in a strategic combination to form AtaiBeckley, a global leader in transformative mental health therapies. The acquisition, approved by 98% of shareholders, brings together a robust pipeline of investigational treatments, including a Phase 3-ready asset, BPL-003, and positions the company to potentially transform the treatment landscape for serious mental health conditions. The company is well-financed to fund operations through 2029 and has a strong leadership team in place to execute its mission.
The most recent analyst rating on (ATAI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
On November 4, 2025, ATAI Life Sciences held an extraordinary general meeting to discuss the acquisition of Beckley Psytech Limited and the company’s redomiciliation to Delaware. Shareholders approved several proposals, including the acquisition, issuance of shares, and appointment of new directors, indicating strong support for the company’s strategic moves. The completion of the redomiciliation is still subject to certain conditions.
The most recent analyst rating on (ATAI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
On October 20, 2025, atai Life Sciences announced the successful closing of its public offering of 27,283,750 common shares, raising approximately $149.5 million. The proceeds, along with existing cash resources, will fund the advancement of clinical trials for its product candidates, including the Phase 3 program for BPL-003 and Phase 2 trials for VLS-01 and EMP-01. This financing is expected to support operations into 2029, reflecting strong investor confidence in atai’s mission to transform mental health treatment.
The most recent analyst rating on (ATAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
On October 16, 2025, atai Life Sciences and Beckley Psytech announced that the U.S. FDA granted Breakthrough Therapy designation to BPL-003, an intranasal formulation for treatment-resistant depression. This designation, following positive Phase 2b trial results, highlights BPL-003’s potential to significantly improve depressive symptoms rapidly and durably, fitting into existing treatment paradigms. The designation is expected to expedite the development and regulatory review process, positioning BPL-003 for Phase 3 trials in 2026, and underscores the potential impact on patients and the mental health treatment landscape.
The most recent analyst rating on (ATAI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
ATAI Life Sciences N.V. has announced a share purchase agreement dated June 2, 2025, to acquire the remaining issued share capital of Beckley Psytech Limited, a company based in England and Wales. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and other conditions. This acquisition could potentially enhance ATAI’s position in the mental health treatment industry, although there are risks related to the completion and benefits realization of the transaction.
The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
ATAI Life Sciences announced a share purchase agreement dated June 2, 2025, to acquire the remaining shares of Beckley Psytech Limited, a company based in England and Wales. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and other customary conditions, potentially impacting ATAI’s market position and operational capabilities.
The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
On September 23, 2025, ATAI Life Sciences and Beckley Psytech announced positive results from a Phase 2a study of BPL-003, an intranasal formulation for treatment-resistant depression. The study demonstrated that a two-dose regimen of BPL-003 led to significant reductions in depression scores and improved remission rates, with sustained effects and a strong safety profile. These findings support further development and regulatory discussions for Phase 3 trials, potentially enhancing ATAI’s position in the mental health treatment industry.
The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, leveraging both psychedelic and non-psychedelic compounds. The company recently released its earnings report for the quarter ending June 30, 2025, highlighting its ongoing efforts in advancing its diverse pipeline of psychiatric product candidates.